CYCLACEL PHARMACEUTICALS INC (CYCC) Stock Analyst Earnings Estimates
NASDAQ:CYCC - Nasdaq - US23254L8019 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 420K | 54.06K -87.13% | 102K 88.68% | 102K | 82.194M 80,482.35% | 120.44M 46.53% | 145.3M 20.64% | 156.78M 7.90% | 162.76M 3.81% | |||
| EBITDA YoY % growth | -22.9M -115.63% | -27.63M -20.66% | -25.422M 7.99% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -22.94M -115.60% | -27.66M -20.58% | -25.453M 7.98% | -12.758M 49.88% | -9.694M 24.02% | -9.897M -2.09% | 71.988M 827.37% | 110.02M 52.83% | 134.66M 22.40% | 145.92M 8.36% | 151.67M 3.94% | |
| Operating Margin | N/A | N/A | -6,060.24% | -23,600.00% | -9,504.00% | -9,703.00% | 87.58% | 91.35% | 92.68% | 93.07% | 93.19% | |
| EPS YoY % growth | -2.14 44.70% | -10.30 -381.31% | -27.23 -164.37% | -1.99 92.70% | -1.20 39.49% | -1.14 5.08% | 3.74 427.68% | 5.60 49.59% | 5.40 -3.64% | 5.71 5.86% | 5.80 1.61% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.30 95.25% | -0.30 86.97% | -0.31 57.50% | -0.31 -70.00% | -0.31 -3.45% |
| Revenue Q2Q % growth | 10.2K -67.10% | 25.5K -12.07% | 25.5K 537.50% | 25.5K 155.00% | 25.5K 150.00% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -2.379M 55.62% | -2.387M 45.19% | -2.411M 33.83% | -2.436M -11.89% | -2.46M -3.43% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.18 97.55% | -0.57 | 0.39 | 68.20% |
| Q2 2024 Q2Q % growth | -0.72 89.09% | -1.46 | 0.74 | 50.81% |
| Q1 2024 Q2Q % growth | -2.27 67.80% | -4.84 | 2.57 | 53.10% |
| Q4 2023 Q2Q % growth | -6.23 30.78% | -6.01 | -0.22 | -3.64% |
| Q3 2023 Q2Q % growth | -7.35 -1,650.00% | -5.56 | -1.79 | -32.22% |
| Q2 2023 Q2Q % growth | -6.60 -1,334.78% | -7.70 | 1.10 | 14.30% |
| Q1 2023 Q2Q % growth | -7.05 -1,578.57% | -10.15 | 3.10 | 30.53% |
| Q4 2022 Q2Q % growth | -9.00 -1,566.67% | -7.38 | -1.62 | -21.91% |
| Q3 2022 Q2Q % growth | -0.42 22.22% | -0.57 | 0.15 | 26.91% |
| Q2 2022 Q2Q % growth | -0.46 17.86% | -0.64 | 0.18 | 27.87% |
| Q1 2022 Q2Q % growth | -0.42 16.00% | -0.70 | 0.28 | 39.82% |
| Q4 2021 Q2Q % growth | -0.54 59.70% | -0.67 | 0.13 | 18.97% |
| Q3 2021 Q2Q % growth | -0.54 -14.89% | -0.66 | 0.12 | 18.55% |
| Q2 2021 Q2Q % growth | -0.56 3.45% | -0.51 | -0.05 | -10.54% |
| Q1 2021 Q2Q % growth | -0.50 66.22% | -0.50 | 0.00 | -0.72% |
| Q4 2020 Q2Q % growth | -1.34 52.14% | -0.53 | -0.81 | -155.09% |
| Q3 2020 Q2Q % growth | -0.47 78.64% | -0.56 | 0.09 | 16.22% |
| Q2 2020 Q2Q % growth | -0.58 73.64% | -0.48 | -0.10 | -21.85% |
| Q1 2020 Q2Q % growth | -1.48 47.14% | -2.96 | 1.48 | 49.97% |
| Q4 2019 Q2Q % growth | -2.80 | -2.75 | -0.05 | -1.67% |
| Q3 2019 Q2Q % growth | -2.20 | -3.20 | 1.00 | 31.17% |
| Q2 2019 Q2Q % growth | -2.20 | -3.20 | 1.00 | 31.17% |
| Q1 2019 Q2Q % growth | -2.80 | -4.18 | 1.38 | 33.05% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 10K -37.50% | 5.1K | 4.9K | 96.08% |
| Q2 2024 Q2Q % growth | 4K -98.93% | 30.6K | -26.6K | -86.93% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 88.8% | 0% | 37.7% |
| Revenue | 0% | N/A | 0% | 23.26% |